Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q9UIJ5 (
Rec
)
58,342
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Clinical recommendations for analgesics in laboratory rodents are usually derived from basic research. However, animal models of pain often involve withdrawal reflexes evoked by threshold-level stimuli, whereas pain associated with surgery or disease involves injury and inflammation. Moreover, the analgesics used in research tend to be chosen as exemplars of a drug class, without regard for whether the route of administration is practical, whether the drug has useful kinetics or whether the side effects are tolerable. This paper provides data on the efficacy of drugs from four classes, using the formalin test as a model of injury-induced pain. Formalin (50 microliters, 2.5 per cent) was injected subcutaneously into a rat's paw and the behavioural response (lifting or licking of the paw) was recorded.
Buprenorphine
at 0.1 mg/kg and dipyrone at 200 mg/kg completely suppressed the pain responses. When formalin was injected six hours after buprenorphine or dipyrone, pain scores were 30 per cent of control scores. In the absence of pain and handling, 0.6 mg/kg buprenorphine was lethal to 25 per cent of rats. Locomotor activity was slightly depressed by 300 mg/kg dipyrone. Xylazine at 2 mg/kg suppressed pain responses, but the analgesia had decreased to less than 50 per cent after two hours and the effects were variable thereafter; at 8 mg/kg rats were unresponsive to a strong pinch. Acepromazine at 2.5 mg/kg reduced pain to 20 per cent of control scores and this level of analgesia was maintained for six hours; neuroleptic effects were prominent at 5 mg/kg.
Vet
Rec
1997 May 24
PMID:Options for management of acute pain in the rat. 918 12
Twenty-eight dogs were randomly allocated into two groups. They were premedicated with either 10 or 20 microg/kg buprenorphine and 0.05 mg/kg acepromazine administered intramuscularly, and then anaesthetised with intravenous thiopentone to effect and maintained with isoflurane in 100 per cent oxygen. The dogs underwent routine castration, and a second dose of 10 microg/kg buprenorphine was administered four hours after the first or 20 microg/kg six hours after the first dose. Levels of pain and sedation were scored on a visual analogue scale and in terms of the dogs' requirement for rescue analgesia, and mechanical nociceptive thresholds were measured at the hock and wound at premedication and one, two, three, four, five, six, seven, 10 and 21 to 22 hours later. Pain scores were low in both groups, with a trend for lower scores in the high dose group; administration of the second dose of buprenorphine further decreased the pain scores.
Buprenorphine
produced good preoperative sedation and the level of sedation decreased over time after surgery. Administration of the second high dose of buprenorphine did not increase the level of sedation. Both doses of buprenorphine prevented hyperalgesia at the wound and hock postoperatively. Three dogs given the low dose and one dog given the high dose required rescue analgesia with carprofen.
Vet
Rec
2006 Nov 18
PMID:Effects of two doses of buprenorphine four or six hours apart on nociceptive thresholds, pain and sedation in dogs after castration. 1711 81
Buprenorphine
has recently obtained UK Marketing Authorisation for horses. The analgesic effects are long lasting, and have considerable potential for postoperative pain relief. This observer blinded, randomised study aimed to evaluate postsurgical analgesia in ponies premedicated with buprenorphine prior to castration under intravenous anaesthesia. Ponies received either 0.01 mg/kg bodyweight (BW) buprenorphine (group B) or an equivalent volume of 5 per cent glucose (group C) given intravenously before induction of anaesthesia. Pain was assessed and recorded using dynamic interactive visual analogue scores (DIVAS 0-100) and a Simple Descriptive Scale (SDS 0-3) (high scores=most pain) before and 1, 3, 6, 9, 12 and 24 hours after anaesthesia. Rescue analgesia was given if DIVAS>40 mm. Data were analysed using the Mann-Whitney U test at P<0.05. Median (range) areas under the curve for DIVAS were 63 (0-383) mm hour in group B and 209 (0-391) mm hour in group C (P=0.0348). The SDS was lower in group B than in group C (P=0.038). Three group B and five group C animals required rescue analgesia.
Buprenorphine
did not produce any serious adverse effects.
Buprenorphine
at 0.01 mg/kg BW intravenously administered before anaesthesia provided near-comprehensive postoperative analgesia after surgical castration in ponies.
Vet
Rec
2013 Jun 15
PMID:Postcastration analgesia in ponies using buprenorphine hydrochloride. 2373 17